FDA Approves Takeda’s GAMMAGARD LIQUID ERC, First Low-IgA Ready-to-Use Therapy
Takeda announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC, the first and only ready-to-use liquid immunoglobulin (IG) therapy with low…
Read More...
Read More...
